In this episode, I discuss corneal disease and treatments with David Eveleth, PhD, the founder, president and CEO of Trefoil Therapeutics.

Brought to you by Alcon

·       Welcome to another exciting episode of Eye Care insider :14

·       Intro David Eveleth, PhD :47

·       Eveleth’s background 1:05

·       What’s the treatment landscape now for corneal diseases and where are we falling short for patients? 2:59

·       The origins of Trefoil Therapeutics 7:27

·       FGF-1: Is it just important in the endothelium or is it also important in the epithelium? 11:47

·       What is your current lead investigational candidate? 14:01

·       When do you expect another read out of clinical data? 21:47

·       An adjunctive therapy with cataract surgery 18:27

·       What is the timeline of administration to patients? 19:24

·       When do you expect a readout of clinical data? 20:49

·       Is it possible to use this also for the epithelium? 21:39

·       What are the most important challenges facing the ophthalmic industry? What is the most important factor to look for? 24:07

·       For more information about David Eveleth, PhD, and Trefoil Therapeutics, visit www.trefoiltherapeutics.com 25:53

·       Corneal disease can be fixed and better vision is possible 26:44

·       Thanks for listening 27:04

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can find follow Trefoil Therapeutics on Twitter @TrefoilThera.

David Eveleth, PhD, is the president and CEO of Trefoil Therapeutics.

Disclosures: Eveleth is the founder, CEO and shareholder of Trefoil Therapeutics. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

In this episode, I chat with Nancy Lurker, CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials.

Brought to you by Alcon

·       Welcome to another exciting episode of Eye Care insider :13

·       Intro Nancy Lurker :22

·       Lurker’s background :58

·       EyePoint Pharmaceuticals: the origin and transition 2:29

·       Yutiq and long-acting drug delivery systems 6:07

·       Additional indications for Yutiq 8:30

·       What is the key factor in delivering this longer durability? 16:13

·       Any consideration of looking at superiority of visual acuity and anatomical OCT gains? 21:47

·       Is the primary focus wet AMD? Or are you also looking at NPDR and DME as potential indications? 24:19

·       Investor information and neural protection data 29:01

·       What is the most important issue that the field of ophthalmology is currently facing? 30:38

·       Thanks for listening 32:37

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can find Nancy Lurker at @EyePointCEO and @EyePointPharma.

Nancy Lurker is the board director and CEO of EyePoint Pharmaceuticals.

Disclosures: Lurker is the board director and CEO of EyePoint Pharmaceuticals. Mali reports he is founder and CEO of Mali Enterprises; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

In this episode, I discuss Samsara Vision’s SING IMT and its benefits of vision improvement for patients with AMD with Rebecca Kammer, OD, PhD.

Brought to you by Alcon

·       Welcome to another exciting episode of Eye Care insider :14

·       Intro for Rebecca Kammer, OD, PhD :27

·       Dr. Kammer’s background 1:28

·       Defining late-stage AMD patients and treatments available 5:11

·       The SING IMT 9:46

·       US Concerto Study Website – to learn more about the study 13:13

·       Visual acuity and the SING IMT 13:48

·       US trial, recruitment and patient eligibility 17:18

·       Contact toll-free 1-866-393-3767 discuss eligibility, participation and questions 20:39

·       SING IMT as an option for patients 22:55

·       Thanks for listening 27:30

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can reach Dr. Kammer at rkammer@samsaravision.com.

Rebecca Kammer, OD, PhD, is the vice president of worldwide clinical and medical affairs for Samsara Vision, Inc., an adjunct professor at University of California, Irvine and a diplomate in low vision of the American Academy of Optometry.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI. Kammer reports being a clinical advisor to Biovisics and Eyedaptic.

In this episode, I share my top five predictions for 2023 in the field of ophthalmology.

Brought to you by Alcon

• Welcome to another exciting episode of Eye Care insider :52
• My review of the top five predictions in ophthalmology 1:03
• Prediction #1 – Vabysmo and anti-VEGF market 1:53
• Prediction #2 – FDA approval for GA treatment 4:26
• Prediction #3 – SNAPS eye shield for ocular protection 6:06
• Prediction #4 – biosimilars and the ophthalmic therapeutic marketplace 10:08
• Prediction #5 – retina analytical tools 12:27
• Thanks for listening 14:30

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

In this episode, I share my thoughts about the five greatest innovations of the 21st century in the field of ophthalmology and how they have changed patient outcomes for the better.

Brought to you by Alcon

• Welcome to another exciting episode of Eye Care insider :50
• My review of the top five innovations in ophthalmology 1:02
• Greatest Innovation #1 – anti-VEGF medications 2:06
• Greatest Innovation #2 – intraocular lens implantation technology 3:26
• Greatest Innovation #3 – electronic medical records 4:08
• Greatest Innovation #4 – optical coherence tomography 5:48
• Greatest Innovation #5 – telemedicine 6:35
• Thanks for listening 7:44

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular  Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, I share my review of the hot topics from the AAO 2022 annual meeting and share my thoughts on the new data shared about drug trials and treatments.

Brought to you by Alcon

• Welcome to another exciting episode of Eye Care insider :53
• My review of the hot topics from the AAO 2022 annual meeting 2:20
• Hot Topic #1 – wet AMD treatments 2:40
• Hot Topic #2 – high-dose Eylea 6:20
• Hot Topic #3 – geographic atrophy treatments 10:24
• Thanks for listening 16:04

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, I share my preview of the hot topics for the upcoming AAO 2022 annual meeting, including my thoughts on ocular gene therapy and new treatments in the works.

• Welcome to another exciting episode of Eye Care insider :52
• My preview of hot topics for the upcoming AAO 2022 annual meeting 1:04
• Hot Topic #1 – new treatments for dry AMD or geographic atrophy 2:43
• Hot Topic #2 – wet AMD management 5:55
• Hot Topic #3 – ocular gene therapy 7:56
• Hot Topic #4 – biosimilars 9:17
• Thanks for listening 11:22

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, Jose O. Segura, wealth management advisor and certified business exit planner, discusses establishing objectives within financial planning and organization, how to diversify your portfolio in ever-changing markets and more.

• Intro :38
• Welcome to another episode of Eye Care insider :52
• About Jose Segura 1:03
• For people that are listening for the first time, do you mind giving a brief of your background? 1:32
• What are, in your opinion, some best practices in regard to financial planning? 2:58
• Process for financial organization and seeking out advisors. 10:09
• Can you talk about the importance of portfolio diversification? 12:07
• Importance of maintaining your overall focus on financial planning and strategies when markets are effected. 16:56
• Could you give us one pearl for our listeners, or one key economic update that you think would be really important to the current economic situation right now? 18:49
• Thank you Jose 23:09
• Any final words to our listeners? 23:11
• Outro 23:35

Jose O. Segura, is a wealth management advisor and certified business exit planner.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. For more information about Segura, visit www.joseosegura.com, reach him by email at jose_segura@wagllc.com, or call 518-867-3210 x104.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Segura reports he is a registered Representative and Financial Advisor of Park Avenue Securities LLC (PAS), 355 Lexington Avenue, 9 Fl., New York, NY 10017, 212-541-8800.